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representative 10-point scale of exclusiveness. Potential
cost savings for typical trial scenarios range in millions
of dollars. As the response rate for controls approaches
50%, the proper choice of inclusion criteria can mean
the difference between a successful trial and a failed
trial.
CONCLUSION: Early formal estimation of optimal inclusion criteria allows planning of clinical trials to avoid
high costs, excessive delays, and moral hazards of Type
II errors.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Abstract
AIM: To present statistical tools to model and optimize
the cost of a randomized clinical trial as a function of
the stringency of patient inclusion criteria.

Core tip: This paper presents statistical tools to model
and optimize the cost of a randomized clinical trial as a
function of the stringency of patient inclusion criteria.
The patient numbers and total cost are strongly related to the choice of the cutoff for inclusion. Clear cost
minimums exist for many realistic scenarios. Potential
cost savings for typical trial scenarios range in millions
of dollars. Early formal estimation of optimal inclusion
criteria allows planning of clinical trials to avoid high
costs, excessive delays, and moral hazards of type Ⅱ
errors.

METHODS: We consider a two treatment, dichotomous outcome trial that includes a proportion of patients who are strong responders to the tested intervention. Patients are screened for inclusion using an
arbitrary number of test results that are combined into
an aggregate suitability score. The screening score is
regarded as a diagnostic test for the responsive phenotype, having a specific cutoff value for inclusion and
a particular sensitivity and specificity. The cutoff is a
measure of stringency of inclusion criteria. Total cost is
modeled as a function of the cutoff value, number of
patients screened, the number of patients included, the
case occurrence rate, response probabilities for control
and experimental treatments, and the trial duration required to produce a statistically significant result with a
specified power. Regression methods are developed to
estimate relevant model parameters from pilot data in
an adaptive trial design.
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RESULTS: The patient numbers and total cost are
strongly related to the choice of the cutoff for inclusion.
Clear cost minimums exist between 5.6 and 6.1 on a
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INTRODUCTION
Clinical trials are too costly and take too long to com-
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plete. High costs of clinical trials add significantly to the
ultimate costs of new medicines and medical devices.
Delay in completion of a trial due to inefficient trial design can postpone, sometimes indefinitely, the transfer of
promising new therapies from bench to bedside. Assuming that a true positive treatment effect exists, strategies
are needed for finding the most direct route to a statistically significant result using the smallest numbers of patients.
When a genuinely responsive subset of patients is
diluted with many patients who are genetically or physiologically ill suited to respond to a new experimental
treatment, the numbers of patients that must be studied
to disprove the null hypothesis increases dramatically.
Type Ⅱ errors in statistical inference (accepting the null
hypothesis when it is false) can arise, and a useful drug,
device, or procedure, which could have benefited some
classes of patients, may be lost to further development.
This situation is especially likely when only a fraction of
patients in the treatment group respond well to the tested
intervention, and when the control or comparison group
is treated with a known, effective standard therapy, as is
often done for ethical reasons. In this situation patient
selection criteria are crucial.
An era of personalized medicine is emerging in which
novel biochemical markers will be found for the diagnosis
of cancer and other diseases[1]. When a genetic variation
is linked to a specific drug effect, it becomes a biomarker
that helps predict how an individual will react to a drug[2].
The treatment of cancer, in particular, is moving towards
the use of more specific therapies that are targeted to
each tumor type. To facilitate this shift, tests are being developed to identify those individuals who are most likely
to benefit from particular treatments on the basis of the
genes expressed by their tumors[3]. Such biomarkers may
identify patients who will experience the most drug benefit
and fewest side effects. In this setting innovative thinking
about clinical trial design is needed to increase the proportion of patients receiving the best individual treatment, and
to complete the trial more rapidly with fewer patients. There
is also an ethical dimension to more efficient trial design:
increasing the probability of a patient’s being allocated to a
successful treatment. With targeted, personalized therapy
the study patients do not have to pay a high price for
the benefit of future patients[4]. The challenge moving
forward is to identify optimal trial design in a population
with known biomarker levels, based upon screening data,
and to identify the optimal allocation of patients to treatment groups, based upon mathematical and computer
simulation of the trial.
Here we consider a paradigm in which either a phase
Ⅱ trial data or an adaptive trial design provides pilot data
describing responsiveness to the tested intervention in
various types of patients. We consider the planning of
a follow-on phase Ⅲ trial, in particular a two-treatment
randomized clinical trial, including a control group and
an experimental group and having a dichotomous end
point such as response vs non-response to treatment.
The definition of response is at the discretion of the in-
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vestigator and is based on clinically desirable outcomes.
Examples include disease free survival from cancer for a
period of one year, induction of a state of clinical remission in leukemia, or resuscitation from cardiac arrest with
a measurable pulse and blood pressure. The primary endpoints of the future trial are the proportions of patients
that respond in the experimental group and in the control
group.
The goal of the present research is to create a formal
mathematical model of the planned randomized trial
that will allow one to define and predict an optimal set
of inclusion criteria. Such criteria would screen out nonresponsive patient types and achieve a statistically significant result with the smallest number of patients and the
lowest overall cost in both time and resources. In such
a trial patients who are prospective candidates having
an appropriate diagnosis would be screened according a
list of possible metrics, such as age, tumor stage, or biomarker level. The screening metrics, here denoted x1, x2, …,
etc. are combined mathematically by a classifier function,
F (x1, x2, …), based on pilot data to obtain a single overall
score, x = F (x1, x2, …), which is a predictor of successful
response. Future patients for whom x equals or exceeds
a cutoff value xc will be included in the trial, and patients
for whom x < xc will be excluded. Combinations of x1, x2,
…, etc. yielding values of x ≥ xc constitute the inclusion
criteria for the study. The questions addressed by this paper are how to define a satisfactory classifier F (x1, x2, …)
and how to best choose xc to produce a statistically significant positive result with minimal time and cost, assuming
an alternative hypothesis of a true treatment effect.
To help predict the most favorable inclusion criteria, it is helpful to regard the screening process and the
function F (x1, x2, …) as a diagnostic test, for which the
concepts of sensitivity and specificity apply. This paper
demonstrates how one can use data from a one-armed
phase Ⅱ study or early-stage pilot data from an adaptive
trail design to create a suitable classifier F (x1, x2, …) for
discriminating responders from non-responders and also
to predict the best cutoff, xc, for inclusion of future patients.

MATERIALS AND METHODS
Formulation of the problem
Suppose that a planned, two-arm, randomized clinical
trial begins with evaluation of N possible candidates having a standard clinical diagnosis such as biopsy proven
carcinoma of the breast. Suppose further that this population is heterogeneous in the sense that a proportion,
q, of the patients are biologically well suited to respond
to the experimental treatment (call them type 1 patients)
having success probability π1 ≈ 1, and the remaining proportion, 1 - q, of the patients are biologically ill suited to
respond to the experimental treatment (call them type 2
patients) having success probability π2 ≈ 0. It is normally
not possible to predict in advance which patients will
respond, but one can try to establish favorable inclusion
criteria based on certain screening data. These data may
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and study numbers will be small. On the other hand, as
the cutoff xc, is reduced, the entry criteria become more
loose. Sensitivity increases, but specificity decreases. The
population of patients included in the trail is diluted with
more and more non-responding type 2 patients. If q is
small, the time and cost required to establish a significant
treatment effect may become prohibitive.
It is reasonable to use N, the number of candidates
initially considered for the trial before the screening process, as a measure of the cost of screening and also as
one measure of the time required to complete the study.
(If extensive long term follow-up is required, a constant
plus N can be substituted.) It is also reasonable to use
N’ = Nqftp + N (1 - q )ffp , the actual number of patients
enrolled in the study, as a measure of the cost of treating
and managing the patients over the course of the trial.
The mathematical treatment that follows includes
several parts with the following objectives: (1) to create a
formal mathematical model of the proposed randomized
trial, given preliminary screening and outcome data; (2) to
illustrate how such a model can be used to estimate the
probability distribution of a test statistic describing the
outcome of the trial; (3) to exercise the model to predict
the number, N, of patients that must be screened and
the number, N’, of patients that must be included to reject the null hypothesis with a specified power, given the
sensitivity and specificity of the screening process; (4) to
characterize the sensitivity and specificity of the screening process as a receiver operating characteristic (ROC)
curve; and (5) to compute the cost of the trial as a function of N and N’ and to demonstrate how the cost varies
as a function of the stringency of the inclusion criteria,
based on the cutoff xc, and in turn to determine if there
is a “best” cutoff, xc, for which a cost function of N and
N’ is minimized.

Type 2 patients
Type 1 patients

Cut-off

Probability density

0.8

0.6

0.4

0.2

0.0

-1.5

-0.5

0.5

1.5

2.5

x

Figure 1 Separation of patient response phenotypes to a tested treatment
according to an aggregate predictive variable, x. The fraction of type 1
responders to the right of the cutoff is the true positive fraction. The fraction of
type 2 non-responders to the right of the cutoff is the false positive fraction. In
this general example the units of x are arbitrary.

be a simple as age, gender, and stage of disease or may
include sophisticated measures of biomarkers.
If the screening procedure had 100% sensitivity and
100% specificity for detecting guaranteed responsive type
1 individuals, who are very likely to respond to the new
therapy, then the inclusion decision would be trivial: only
type 1s would be included. In the more common situation potential good responders are difficult to identify,
and a battery of imperfect metrics is employed. Suppose
that such a battery of tests exists and that the test results
x1, x2, etc. are combined in a single overall suitability test
score, x = F (x1, x2, …). Type 1 and type 2 patients are
likely to be distributed along the x-scale as shown in Figure 1, with significant overlap. Overlap of the distributions leads to meaningful fractions of false positive evaluations and false negative evaluations for the presence of
the treatment responsive phenotype, given any chosen
cutoff, xc , for entry into the study.
In this sense we can regard the process of patient
selection as a “diagnostic test”, for which the concepts of
sensitivity (true positive fraction, ftp) and specificity (true
negative fraction, ftn) apply. The false positive fraction, ffp
= 1 - ftn. If q is the fraction of type 1 individuals in the
initial population of N patients and if 1 - q is the fraction
of type 2 individuals, then Nqftp type 1s and N (1 - q )ffp
type 2s will be selected for inclusion in the trial. As the
cutoff xc, is raised, the entry criteria become more strict,
specificity for the responsive type 1 phenotype increases,
but sensitivity decreases. Some potential good responders are excluded, and the overall study size is decreased,
reducing its statistical power. In the limiting case overstrict inclusion criteria will reject nearly all patients. The
time required to find perfect candidates will be excessive,
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Creating a model using binomial distributions
Suppose, as before, that N patients are available to be
screened for inclusion in a future randomized clinical trial
comparing experimental and control groups. The end
point of the trial is dichotomous. A fraction, 0 < q < 1,
of patients will respond well to the experimental treatment based on their genetics or physiology. Denote these
good responding individuals as type 1 patients and remainder of non-responding individuals as type 2 patients.
A screening procedure is performed having overall sensitivity ftp, specificity ftn, and false positive fraction ffp = 1
- ftn . After screening and evaluation n = ftpNq type 1 patients and m = ffp N(1 - q) type 2 patients will be selected
for inclusion in the trial. These selected patients will be
randomized into control and treatment groups, which for
generality need not be equal, having α (n + m) patients in
the experimental group and (1 - α)(n + m) patients in the
control group for 0 < α < 1.
Consider a model in which the probability of favorable outcome after the experimental treatment among
type 1s is π1 = 1, and the probability of favorable outcome after the experimental treatment among type 2s is
π2 = 0. To allow for the possibility that the type 1s and
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Table 1 Expected values of enumeration data in a model trial
H0
Number of successes
(responses)
Total

H1

0.4

Probability density

0.3

Control group

α (np1 + mp2)

(1 - α) (np3 + mp4)

α (n + m)

(1 - α) (n + m)

for patient inclusion. The distribution of z is characterized by its mean and variance, as follows.
From Table 1 the expected value, μ, of the difference
in sampled proportions between the experimental and
control groups is

0.2

m = [n(p1 - p3) + m(p2 - p4)]/(n + m)

0.1

-3

Experimental group

0.0
0

3

The variance of the difference in proportions is the
sum of the variances of the independent sample proportions σ2 = σ2(pE) + σ2(pC). To find the variances note
that the true population probabilities for responses in the
experimental group and the control group are

6

Test statistic, Z

Figure 2 Calculation of power from probability density distributions for
the null hypothesis (H0) and for an alternative hypothesis (H1). The dashed
line shows critical value for significance (1.96 for two-tailed P < 0.05). The area
under the thick curve to the right of the critical value is the statistical power of
the test of H0.

pE = (np1 + mp2)/(m + n)
and
(1b).
pC = (np3 + mp4)/(m + n)
Hence, using the standard formulas for the variances
of binomial distributions[7],

type 2s may also respond differently after the control
treatment, let the probability of favorable outcome after
the control treatment among type 1s be π3 and the probability of favorable outcome to the control treatment
among type 2s be π4 (Numerical values for π3 and π4
will be estimated from pilot data or published literature
as described later). The expected outcome of the trial
is shown in Table 1, showing the mean number of observed responders (successful outcomes) in each group.

2
σ (pE) = [pE(1 - pE)]/[a(n + m)]

and
2
σ (pC) = [pC(1 - pC)]/[(1 - a)(n + m)]

(1c)

with

Predicting statistical outcomes of the trial
Let us use the difference in proportion test for statistical
inference for the purpose of predicting trial size and cost.
(This choice in no way prevents the use of other statistical measures and tests of significance for reporting later
results, including internal meta-analysis of the various
stages[5,6]). The difference in the proportion of responders ∆p = pE - pC between experimental and control groups is
computed and then divided by an estimate, σ , of the standard deviation, σ, of the difference of proportions to
obtain a test statistic z = ∆p/σ . Under the null hypothesis, H0, the expected value of the z-statistic is zero and
the standard deviation of the z-statistic is 1, as shown by
the thin curve in Figure 2.
To explore the predicted N required for a statistically
significant study as a function of model parameters, we
can compute the distribution of the test statistic, z, under
the alternative hypothesis, H1, of a positive effect of experimental treatment. The form of this distribution, represented by the thick curve in Figure 2, is a function of
model parameters, including probabilities π1, π2, π3, and
π4, the number, N, of patients screened and the cutoff
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(1a).

1-pE = (n + m - np1 - mp2)/(n + m)
= [n (1 - p1) + m (1 - p2)]/(n + m)
and similarly for 1 - πC .
Under the null hypothesis of zero treatment effect
compared to control, the expected value of pE - pC = 0,
and the test statistic
pE - pC
z=
2
2
(2)
σ (pE) + σ (pC)
will have mean value z0 = 0 and a standard deviation of
one. That is, z will be distributed to good approximation
as the standard normal distribution under H0.
Under the alternative hypothesis of an expected positive treatment effect the expected value, µ, of pE - pC will
be greater than zero, and the test statistic, z, will have
mean value, z1 > 0 . The value of z1 under H1 is related
to the values of parameters (1a) through (1c) and and
to the critical values for significance testing and the statistical power of the trial. For example, for P < 0.05 the
critical value is 1.96, and for a power of 84%, that is an
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84% probability of detecting a true effect as significant,
then z1 must be 1.0 standard deviation to the right of
the cutoff in Figure 2, so that z1 = 2.96 . To find the N
and inclusion cutoff required to identify as statistically
significant a particular treatment effect with a particular
power we can explicitly evaluate z1 in terms of model
parameters. Then

s

=

0.8

True positive fraction

z1 =

m

1.0

n(p1 - p3) + m(p2 - p4)
m+n
(3a)

pE(1 - pE)
pC(1 - pC)
+
(n
+
m)
(1
a
a)(n + m)

0.0
0.0

After squaring (3a), substituting expressions (1), and simplifying the algebra,
[n (p1 - p3) + (p2 - p4)]2
2
z1 =
p1 (1 - p1)
p2 (1 - p2)
p1 + p2 p3 + p4
+
a

a

+nm

-2

1-a

p1p2
a

1-a

3 4
- 2p p

1-a

+ m2

z1 = N .

a

p4 (1 - p4)
+
1-a

[ftpq + ffp (1-q)] . [ftpq (p1 - p3) + ffp(1 - q)(p2 - p4)]2

p1 (1-p1)

p1 + p2 p3 + p4
a
a + 1-a
+ ftpffpq(1 - q)
ftp2q2
3 (1-p3)
p1p2 p3p4
+ p
-2
-2
1-a
1-a
a
p2 (1-p2)
2
fp

2

+ f (1 - q)

a

p4 (1-p4)
+
1-a

(4)
which can be solved for N as a function of model parameters ftp, ffp, q, zc, π1 through π4 , and the target power and
level of significance represented by z1 .
Expression (4) predicts N as a function of the proportion, q, of good responders in the population, the
sensitivity and specificity of the screening procedure
for inclusion into the study, and the effectiveness of the
treatment in controls. Note since we use the square of
z1 to get N, the resulting N could be that for a significant
positive result with pE > pC or a significant negative result
with pC > pE. As expected, the required N becomes infinite, given the other parameters, when the null hypothesis
is exactly true and the expected value of pE equals the
expected value of pC.
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0.4
0.6
False positive fraction

0.8

1.0

Characterizing the screening process as an ROC curve
To explore the effects of more selective vs less selective
inclusion criteria, one can examine paired combinations
of true positive fractions and false positive fractions for
a typical screening procedure as defined by a ROC curve.
An ROC curve is a plot of ftp as a function of ffp in the
unit square, as the cutoff value of decision variable, x, is
gradually reduced from the maximum possible value of x
toward the minimum possible value. A typical ROC curve
is illustrated in Figure 3. Each point on the curve represents a realistic combination of ftp and ffp (sensitivity and
1- specificity) for a particular classifier used to distinguish
type 1 vs type 2 patients.
In this context the ROC curve describes a family of
cutoff values in the x-domain for partially overlapping
distributions of good responding, type 1 patients and
non-responding, type 2 patients. An ROC curve that is
shifted upward and to the left indicates a better discriminating screening test. The ROC curve provides a useful
mathematical model of stricter vs looser inclusion criteria
for a clinical trial.
With this model one can explore the influence of
inclusion criteria on the size and cost of the clinical trial.
The top curve in Figure 4 is a representative plot of N
from expression (4) as a function of cutoff value xc. N
represents the number of patients screened in a hypothetical clinical trial with a statistically significant positive
result (P = 0.05).
The number of patients actually enrolled in the trial
after screening, according to the definitions of the model,
is
(5).
N’ = n + m = ftpNq + ffpN(1 - q)

(3b)
Then substituting n = f tpqN and m = f tpN(1 - q)
gives,
2

0.2

Figure 3 A sample receiver operating characteristic curve for a hypothetical screening test. In this example type 1 patients had screening scores, x,
with a mean of 5.5 and a standard deviation of 1; type 2 patients had screening
scores, x, with a mean of 4 and a standard deviation of 1. As the cutoff value xc
is swept from 1.0 toward zero, a family of true positive and false positive fractions is created to generate the receiver operating characteristic (ROC) curve.

Predicting N and N’ required to reject the null hypothesis
with a specified power

3 (1 - p3)
+ p

0.4

0.2

Knowing the target location of z1 , one can estimate the
statistical distribution of the results of the proposed trial,
based upon the model parameters and the pilot screening
and outcome data.

n2

0.6

This number is plotted as the bottom curve in Figure
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10

800

8
Cost (millions of dollars)

1000

600
N
400
Screened
200
0

Enrolled

0

2

4

xc

6

8

6
4
2
0

10

0

2

4

6

10

Figure 5 Cost estimates in a model study of heterogeneous responders.
Cost constants in thousands of dollars are as follows: screening cost per case
c1 = 1, treatment cost c2 = 10, opportunity cost c3 = 100/yr, case rate r = 50/yr,
follow up time t =1 yr. Other details as in Figure 4.

Figure 4 Numbers of patients screened and enrolled in a model study
of heterogeneous responders having a statistically significant positive
result. For this model the proportion of type 1, good responders q = 0.2, the response probability for type 1 patients, p1 = 1.0, the response probability for type
2, poor responders, p2 = 0. The response probabilities for both phenotypes to
the control treatment, p3 and p4 both equal 0.2. The mean value of the z statistic for the alternative hypothesis is 2.96 (84% power for the trial). The proportion
of patients, α, assigned to the experimental group is 0.5.

the study. In this case the total cost of the study is
Cost = c1N + c2N’ + c3(N/r + t).

4 for one hypothetical example.
In this example the mean composite screening score,
xc, for responders is 5.5 and the standard deviation is 1.
The mean composite screening score for non-responders
is 4.0 with a standard deviation of 1. The ROC curve for
this scenario is that of Figure 3. A value of cutoff xc < 2
means that all comers were included in the study. That is,
there was no selection. A cutoff > 8 means that virtually
all patients were excluded. In the mid range of inclusion
criteria, there remains a strong effect of screening selectivity on the number of patients required to produce a
significant result, given the alternative hypothesis. There
is a clear optimal cutoff for patient selection near xc = 5.6
that minimizes the number of patients, N, with an initial
diagnosis needed to produce a statistically significant
positive result.

(6)

Additional cost terms can be added, if desired, such
as performance site start-up costs, which would be related to N divided by the number of proposed sites. Figure
5 shows for the preceding example in Figure 4 the total
cost calculation for the hypothetical cost constants given
in the figure legend.
The anticipated cost of the study is strongly dependent on the stringency of the inclusion criteria. A low
cost sweet spot exists for a narrow range of inclusion
cutoff values in the range of 5.6 to 6.1 for this model.
The result is consistent with qualitative experience that
good results occur in a reasonable amount of time when
patient selection is targeted and rigorous, but not so rigorous as to choke off the number of patients entering
the trial who might benefit.
A particularly interesting situation arises when the
average response probability for all patients given the
experimental treatment, which is equal to q, is less than
that for type 2 patients given the control treatment. In
Figure 6 we have the situation in which π1 = 1.0 and π2 =
0, and q = 0.2, as before. However, we have π3 = π4 = 0.4.
The experimental drug is much less effective than control treatment for type 2 patients. The cost projections
include a vertical asymptote when the null hypothesis is
exactly true, that is the expected value of pE equals the
expected value of pC. To the right of the dashed line a
significant positive effect, pE > pC, can be detected at the
indicated cost. To the left of the dashed line a significant
negative effect, pC > pE, can be detected. In such situations, which may be quite common in practice, choice of
inclusion criteria could well make the difference between
a futile study and a successful one. Thus the choice of
inclusion criteria clearly can have large effects on the cost
and success of a clinical trial.
The next sections develop methods to construct a
classifier F(x1, x2, … ) and to estimate the model param-

Computing the cost of the trial
A total cost model is easily developed from the forgoing.
The value of N as a function of ftp and ffp is a measure
of the cost of screening, since all suitable patients must
be screened. The value of N’ as a function of ftp and ffp
is a measure of the cost for treatment and monitoring of
enrolled patients, since more enrolled patients will require
more personnel, facilities, coordination, data management, etc. The opportunity cost of delayed revenue from
a successful new product and the opportunity cost of diversion of resources from other worthwhile projects are
related to the duration of the trial.
Let c1 be the cost of screening per patient. Let c2 be
the average cost of treatment per patient in both control and experimental groups. Let c3 be the opportunity
cost per year in delay of marketing a successful drug or
device, that is, the expected revenue divided by the duration of the study. Let r be the case rate, that is, the rate
at which new cases appear for screening, and let t be the
time required for follow up of a patient after entry into

WJM|www.wjgnet.com
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poorly correlated predictors, x1 , x2 …, xk, is

10
Cost (millions of dollars)

k

x = F(x1, x2, ....xk) =

8
6

aixi .

(7)

where constant coefficients

4

ai = xiR - xiNR = piR - piNR,

2
0

i=1

0

2

4
xc

6

and subscript R indicates responders to the experimental
treatment in the preliminary data set and subscript NR
indicates non-responders.
For dichotomous variables xi (0,1) the mean value
XiR is the equal to the proportion, piR, of responders for
whom xi = 1, and mean value xiNR is the equal to the
proportion, piNR, of non-responders for whom xi = 1.
Each coefficient, ai, is the observed difference between
the average value of xi for responders and the average
value of xi for non-responders. If two variables are highly
correlated, for example blood urea nitrogen and serum
creatinine concentration, they can be combined for simplicity and validity into a single dichotomous variable
(renal insufficiency) with a reduction in k. In this way it is
possible to construct an aggregate measure, x, that best
separates the distribution of responders from that of
non-responders. For k dichotomous screening measures
there are 2k possible values of x.
To avoid negative values, the variable x can be rescaled to units of percent with 0 representing the minimum practical value of x and 100 representing the maximum practical value, based on coefficients ai. Some of the
ai may be < 0. The maximal and minimal values of x must
be determined by inspection. Then the re-scaled x-values
x (%) = 100(x - xmin)/(xmax - xmin). Such units are helpful in
any future clinical application of the x-scale, with a patient
requiring a certain number of “points”, xc , on a 0 to 100
scale for inclusion in later stages of the trial.
In turn, one can estimate various possible combinations of false positive fraction, ffp, and true positive fraction, ftp, from the distributions of x-values for responders
and for non-responders. Then the receiver operating
characteristic (ROC) curve describing possible pairs of ftp
and ffp from phase Ⅱ data can be constructed, using alternative cutoff values ranging from the maximum to the
minimum observed values of x.
To obtain the true positive and false positive fractions,
ftp and ffp, for any xc one may proceed in particular as follows. If nNR is the total number of non-responders to the
experimental treatment in the pilot data set, nR is the total
number of responders to the experimental treatment in
pilot data set, xc is a chosen cutoff value in the x-domain,
nNR | x ≥ xc is the number of non-responders for whom
x equals or exceeds the cutoff value, and nR | x ≥ xc is
the number of responders for whom x equals or exceeds
the cutoff value, xc, then

8

Figure 6 Cost estimates in a scenario with good responsiveness to the
control treatment in patients who are non-responsive to the experimental
treatment. p1 = 1.0, p2 = 0, p3 = p4 = 0.4. Other details as in Figure 5. Dashed
line divides the x-domain into regions of a significant negative effect (to the left)
vs a significant positive effect (right). Near xc = 4.4 the cost of disproving the
null hypothesis when it is exactly true becomes infinite.

eters in an adaptive clinical trial, based on a phase Ⅱ pilot
data for treatment outcome and for screening variables,
x1, x2, …etc. Such calculations would allow estimation of
the optimal choice of inclusion criteria in a phase Ⅲ trial
for lowest cost and highest efficiency.
Building a classifier using screening data
Model based prediction of optimal inclusion criteria
requires the creation of an effective classifier to screen
for type 1 patients based upon pilot data. Here we derive a relatively simple and effective linear classifier for
combining an arbitrary number of screening variables,
x1, x2, … xk, to obtain a single overall predictor x = F(x1,
x2, … xk). Using the distributions of combined screening
results, x, for responders and for non-responders to the
experimental treatment, one can estimate the ROC curve
for detection of good responding, type 1 patients. Here
“responders” are those patients observed to have a successful outcome from the experimental treatment. “Nonresponders” are those patients observed to have a poor
outcome from the experimental treatment.
To create a classifier one must first examine screening
data and outcomes in response to the experimental treatment in available preliminary data for all comers. The
association between satisfactory response and possible
predictors x1, x2, … , such as age, sex, tumor stage, or biomarker level, can be judged by plotting the distributions
of each variable for responders and non-responders.
Continuous variables are dichotomized in a convenient
way, using the joint median or a cutoff suggested by the
shapes of the screening data distributions, for example,
age < 50 years = 0 (young) and age ≥ 50 years = 1 (old).
An apparent difference in the proportions of responders vs non-responders suggests that useful predictive
information is captured by variable xi. Combining three
or four features, xi , in different domains of anatomy and
physiology will likely lead to more accurate prediction of
response to therapy.
As shown in Appendix 1, a near optimal choice of a
linear classifier function for k relatively independent or
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Estimating model parameters q, π3, and π4, from pilot
data
Estimation of q: Recall that q is defined as the true
proportion of good responding patients in the screened
population. Using the complete pilot data set, the best
estimate of q is the proportion of responders to the experimental treatment in the initial unscreened population
for which preliminary data are available. This working
estimate of q is denoted q .

expression (4) to obtain projected numbers N of patients
that must be screened and using expression (5) the projected numbers N’ of patients admitted to the trial that
will be required to establish a statistically significant effect under the alternative hypothesis, H1. Incorporation
of the cost model (6) allows reasonable projections of
future trial costs as a function of inclusion criteria, based
upon available data. One then can continue in the future,
operating under inclusion criteria determined by xc. An
adaptive phase Ⅲ trial design is possible in which the
cutoff, xc, is revised on the basis of accrued data at a later
time.

Estimation of π 3 and π 4: To obtain estimates for the
remaining control group parameters π3, and π4, indicating
the response probabilities for type 1 and type 2 patients
to the control treatment, one needs to examine preliminary data, or else previously published data, for patients
given the control treatment and for whom screening
measures are known or can be estimated. For the patients
in the control group, we can impose similar selection criteria based on cutoffs, xc, and corresponding values of ftp,
ffp, and u = ffp/fp, developed from the distributions of responders vs non-responders to experimental (not control)
therapy. For the model of Table 1, where, as before, n =
ffpqN and m = ffp N (1- q)
np3 + mp4
ftp Nq p3 + ffp N(1 - q)p4
=
n+m
ftpNq + ffp N(1 - q)
qp3 + (1-q)p4u

RESULTS
Classification of pilot data
To demonstrate the technique and benefits of model
based selection of inclusion criteria we can use a realistic
data set that is similar, but not identical to that published
by Shaw et al[8] Table 2 shows reconstructed raw data for
this study of a novel drug for the treatment for lung cancer. Patients are characterized by age, sex, smoking history, and the presence of a specific cell surface receptor.
These four predictor variables are dichotomized. The 16
possible combinations of predictors form 16 classes of
patients indicated by the rows of Table 2. The class number is indicated in the left most column. The next four
columns indicate values of the four dichotomous variables. Values of 1 denote old, male, smoking, or receptor
(biomarker) positive patients. Values of 0 denote young,
female, non-smoking, or receptor negative patients. The
next two columns are the counts of patients treated with
the experimental drug in each of the 16 possible classes.
These were reconstructed from published summary data.
The column labeled “NR count” indicates the numbers
of non-responders in each class. The column labeled “R
count” indicates the numbers of responders in each class.
The next two columns are raw counts of patients in each
class treated with the control chemotherapy regimen.
Controls are similarly divided into non-responders (NR)
and responders (R).
To create a classifier for predicting responders to
the experimental drug from the dichotomous screening
variables, the mean values of each dichotomous variable, age, sex, etc. for non-responders and responders to
the experimental treatment are tabulated at the bottom
of Table 2 in columns 2 through 5. These averages are
equal to the proportions of patients labeled successes or
failures with predictor variables of each column equal
to 1. The responder minus non-responder differences in
these variables are the coefficients a1, a2, a3, and a4 in the
linear combination x = a1x1 + a2x2 + a3x3 + a4x4 (expression (7). The values of x for each class are computed
using this function for each of the 16 classes of patients
and shown in the second from the right hand column of
Table 2. The rightmost column of Table 2 shows these
x-values expressed in convenient units of percent, 100(x
- xmin)/(xmax - xmin).

PC (u) =
=

q + (1 - q)u

(9)

If we define q = q/(1-q) for the working estimate, q , then
we can obtain working estimates, p3 and p4 , from the observed relationship
PC(u) =
or

p3q + p4u
q+u

y (u) - PC(u). (θ + u) - p3θ - p4u

(10)

.

(11)

Expression (11) implies that the following regression
analysis may be used to estimate π3 and π4 from pilot
data, given pairs of data points ftp and ffp , and in turn
the ratio, u. Since θ is known from experimental group
data, we can plot for control group data the product y (u)
= pC(u). (q + u) as a function of u and fit a linear, leastsquares line to the data. From the slope and intercept of
the regression line we can obtain estimates, based on all
the control data for
p3 = intercept/q and p4 = slope .

(12)

Often values p3 and p4 from (12) will differ because
stronger patients respond better to both experimental
and control drugs.
In this way one can obtain estimates of all model
parameters based on preliminary or published data. For
each pair of values, ftp and ffp, on the ROC curve corresponding to a given cutoff value xc, one can evaluate
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Table 2 Raw data from a reconstructed study of cancer treatment
Class

Old

Male

Smoke

Receptor

Exp

Exp

NR count R count
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
pNR
pR
Coefficients

1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0.588
0.438
a1
-0.151

1
1
1
1
0
0
0
0
1
1
1
1
0
0
0
0
0.373
0.188
a2
-0.185

1
1
0
0
1
1
0
0
1
1
0
0
1
1
0
0
0.471
0.188
a3
-0.283

1
0
1
0
1
0
1
0
1
0
1
0
1
0
1
0
0.078
0.625
a4
0.547

0
5
0
6
0
9
1
9
0
4
0
4
0
6
3
4

Control

Control

NR count

R count

0
4
0
4
1
6
2
7
0
3
1
3
0
5
4
5

0
2
0
2
0
3
2
3
0
1
0
2
0
2
4
3

0
1
0
1
0
1
3
1
0
0
1
0
0
1
6
1

x

x%

-0.072
-0.619
0.211
-0.336
0.113
-0.434
0.396
-0.151
0.078
-0.468
0.362
-0.185
0.263
-0.283
0.547
0

47
0
71
24
63
16
87
40
60
13
84
37
76
29
100
53

R: Responders; NR: Non-responder.

A

B

0.4

1.0

Non-responders

True positive fraction

Fraction of patients

0.8

Responders

0.3

0.2

0.1

0.6

0.4

0.2

0.0

0.0
0

50

0.0

100

0.2

0.4

0.6

0.8

1.0

False positive fraction

x (%)

Figure 7 Fraction of patients. A: Separation of observed responders and non-responders to the experimental treatment along the x-domain in this reconstructed
preliminary study. The fraction of patients with each x-value is show on the vertical axis. Patients with x-scores over 60% have a much greater likelihood of responding; B:
ROC curve for the screening procedure.

The next step in the analysis requires sorting the classes by x-value from smallest to largest. Owing to the definition of the coefficients ai, responders will be expected
to cluster toward higher values of x and non-responders
will be expected to cluster toward lower values of x. Table
3 shows sorted data for the experimental treatment group
on the left and for the conventional (control) treatment
group on the right. The rows are now sorted by x-values,
determined from the experimental data in Table 2.

perimental treatment in each class. These values are
equivalent to the probability density function defined
over the set of classes. Figure 7A shows the separation
of responders and non-responders to the experimental
treatment along the x-domain. The fraction of patients
with each x-value is shown on the vertical axis. Patients
with x-scores less than 50% respond better to the control
treatment. Patients with x-scores over 80 percent respond
better to the experimental treatment. These results alone
suggest that future studies of the experimental drug for
lung cancer focus on patients with x-scores of 60 or better. Other patients are not likely to benefit, and if these
are included in future trial statistics, a larger N will be re-

Computation of the ROC function
Columns 4 and 5 from the left in Table 3 give the fractions of non-responders and responders to the ex-
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Figure 9 Cost estimates in a realistic test data set for targeted drug
therapy of lung cancer, presented in Tables 2 and 3. Cost constants in thousands of dollars are as follows: screening cost per case c1 = 1, treatment cost
c2 = 10, opportunity cost c3 = 100/year, case rate r = 50/year, follow up time t
=1 year. Cost to the right of the dashed vertical asymptote are for a significant
positive result (experimental treatment better than control). Costs to the left of
the dashed vertical asymptote are for a significant negative result (experimental
treatment worse than control).

1.0

Figure 8 Regression analysis on the last two columns of Table 3. A plot
of the hybrid variable, y = pC(u)(p + u), vs u can be used to evaluate model
parameters p3 and p4. The slope of the regression line is p4, and the intercept
divided by p is p3.

umn 11 of Table 3 is the hybrid variable y = pC(u)(θ + u).
The slope of the regression line of a plot of y vs u is an
estimate of π4, and the intercept divided by θ = q(1 - q) is
an estimate of π3.
Figure 8 shows the regression analysis on the rightmost two columns of Table 3. Both u and y are dimensionless. The intercept of the regression line is 0.165
and the slope is 0.291. Using expression (13), we have
p3 = intercept/q = 0.53 , a n d p4 = slope = 0.29 . T h e
lumped control proportion of responders for all comers
is 0.35. As expected, those classified as strong responders
to the experimental treatment are also somewhat more
likely to respond to the control treatment, an effect that
should be accounted in modeling.

quired to reject the null hypothesis at substantially greater
time and cost.
By integrating the functions plotted in Figure 7A or
constructing a running sum of values in Columns 4 and
5 of Table 3 one can obtain the true positive fractions
and false positive fractions using expression (8) for patients for whom x equals or exceeds a cutoff value indicated in each row. The values of ffp and ftp are shown in
the next two columns. From these values the ROC curve
for screening (ftp as a function of ffp) can be plotted, as
shown in Figure 7B. The values of ftp and ffp are needed
to model the size and cost of the future clinical trial using
equations (4), (5), and (6).
Estimation of q, the population proportion of responders
The value of parameter, q, is best estimated as the proportion of responders for all x-values, or the total of column 3 in Table 3 divided by the total of columns 2 and 3,
namely q̂ = 16/67 = 0.24.

Summary of model parameters
Parameters for the statistical model in this example are
therefore q = 0.24, π1 = 1, π2= 0, π3 = 0.53, and π4 = 0.29.
Exercising the model to predict cost
Figure 9 shows the corresponding cost function for model parameters q = 0.24, π1 = 1, π2.= 0, π3 = 0.53, and π4
= 0.29. Cost was computed using equations (4), (5), and
(6) in succession. Cost coefficients are given in the figure
legend.
This realistic example demonstrates that the choice
of inclusion criteria can have a profound effect on the
outcome of a clinical trial and that adjustment of inclusion criteria by quantitative means can produce protocols
that achieve more with less. In Figure 9 the costs to the
right of the dashed vertical asymptote correspond to a
significant positive result with the experimental treatment
better than control. Inclusion criteria of x > 60 points are
likely to produce such outcomes. Costs to the left of the
dashed vertical asymptote represent a significant negative result (experimental treatment worse than control).

Regression analysis of control data for π3 and π4
The values of parameters π3 and π4 are obtained by the
regression analysis of expressions (9) through (12), using
the control treatment data on the right of Table 3. The
values in column 9, labeled pC|xc ≥ x, are the conditional
probabilities of response given that the cutoff value of
x is at least as great as the x in any particular row. These
values are important to explore, because patients that are
likely to respond to the experimental drug may also tend
to respond to the control treatment, being stronger by
virtue of qualities not measured by x1 through x4. These
probabilities π3 and π4 of response to control treatment
can be estimated from regression analysis of derived variables u and y. The value of u in column 10 equals ffp/ftp ,
based upon the true positive and false positive fractions
from experimental (not control) data. The value y in col-
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Table 3 Analysis of data sorted by x-value
x (%)

Sorted experimental data and ROC curve
NRcount

R count

0
13
16
24

5
4
9
6

1
0
1
1

29
37
40
47
53
60
63
71
76
84
87
100

6
4
9
0
4
0
0
0
0
0
1
3

1
0
1
0
1
0
0
0
0
1
3
6

p (NR|x)

Sorted control data and regression analysis

p (R|x)

ffp

ftp

u

y= pc (q + u)

0.098
0.078
0.176
0.118

0.063
0
0.063
0.063

1.000
0.902
0.824
0.647

1.000
0.938
0.938
0.875

4
3
6
4

2
1
3
2

0.348
0.349
0.356
0.360

1
0.962
0.878
0.739

0.457
0.446
0.424
0.379

0.118
0.078
0.176
0
0.078
0
0
0
0
0
0.02
0.059

0.063
0
0.063
0
0.063
0
0
0
0
0.063
0.188
0.375

0.529
0.412
0.333
0.157
0.157
0.078
0.078
0.078
0.078
0.078
0.078
0.059

0.813
0.750
0.750
0.688
0.688
0.625
0.625
0.625
0.625
0.625
0.563
0.375

5
3
7
0
5
0
1
0
0
1
2
4

2
2
3
0
3
0
0
0
0
0
2
4

0.364
0.378
0.375
0.409
0.409
0.429
0.429
0.462
0.462
0.462
0.500
0.500

0.652
0.549
0.444
0.228
0.228
0.125
0.125
0.125
0.125
0.125
0.139
0.157

0.351
0.326
0.284
0.222
0.222
0.188
0.188
0.203
0.203
0.203
0.227
0.235

NR count R count pc|xc ≥ x

R: Responders; NR: Non-responder.

Inclusion criteria of x < 20 points would likely produce
a significant negative outcome. The dashed vertical line
represents selection criteria that would produce results
entirely consistent with the null hypothesis.

values xi including all treated patients are tabulated and
plotted for each metric, i. Continuous data such as age
or fasting blood sugar concentration are dichotomized,
based on inspection of the frequency distributions for
responders vs non-responders to experimental treatment.
Inherently dichotomous variables, such as male/female,
or diabetic/non-diabetic are allowed also. Treated pilot
patients are sorted into classes of putative responders
and putative non-responders. Differences in proportions
are used to construct a classifier (7), from which one can
construct an ROC curve similar to Figure 3 using expression (8) that specifies possible pairs of ftp and ffp corresponding to different cutoffs for patient inclusion. These
values, together with those of π3, π4 and q, estimated as
described from pilot data and/or from the literature for
standard (control) therapy, allow construction of the cost
function (6) and identification of minimal cost inclusion
criteria going forward.
The present work builds upon the rich literature
describing adaptive clinical trial designs. An adaptive design allows the users to modify a trial during its progress
based on interim results without affecting the validity and
integrity of the trial. There are several subtypes of adaptive designs[15]. A group Sequential design allows for premature termination of a trial based on evidence of strong
efficacy or futility at interim analyses. If a trial shows a
positive result at an early stage, the trial is stopped, leading to an earlier launch of the new drug. If trail shows a
negative result, early stopping avoids wasting resources.
Sequential methods typically lead to savings in sample
size, time, and cost when compared to the classical design
with a fixed sample size[16].
Adaptive design with sample size re-estimation based
upon interim results avoids inaccurate estimation of the
effect size and its variability, which can lead to an underpowered or overpowered study. If a trial is underpowered, it will not be able to detect a clinically meaningful
difference, and consequently could prevent a potentially
effective drug from being delivered to patients. If a trial

DISCUSSION
A major challenge to medical innovation in the modern
era is that when new improved drugs or other treatments
are compared with reasonable, effective standard therapy,
larger and larger trials are needed to detect incremental
benefits at skyrocketing costs. If the effect of experimental treatment is borderline overall and strong in one
subgroup, the overall conclusion is that the experimental
treatment is not significantly different from control. The
potential benefit in the favored subgroup is often not
pursued, owing to limitations of time and cost.
This dilemma has led to the development of adaptive
trial designs[9-14]. If investigators can determine early-on
which types of patients are most likely to benefit from a
novel treatment, then the trail can be re-targeted to favorable patients only. Alternatively, if a particular phenotype,
such as the diabetic state, is found to have untoward
complications compared to other types, then such patients can be excluded going forward, on a rational basis.
Here we show using a model-based approach how it
is possible to minimize the time, cost, and probability of
type Ⅱ error of a clinical trial, by selection of optimal
patient inclusion criteria. This approach provides a route
to planning of a staged clinical trial for efficient use of
resources in the confirmation stage of an adaptive trial
design. It might even provide a way to resurrect good
drugs or devices from failed trials by re-analysis of inclusion criteria used in the past.
The present model based approach can also be applied to data from one-armed preliminary trials of efficacy. Patients receiving the experimental treatment are
characterized according to potential measures x1 through
xk for tightened inclusion criteria. The distributions of
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medical practice by guiding patient-specific treatment selection in the conduct of clinical trials[25].
As such biomarker adaptive trial designs become
implemented, more patients will receive a treatment that
is effective for them. Fewer useful therapies for carefully
selected patients will be lost to further development. The
transition from bench to bedside will be faster, future
patients awaiting better treatments will have less time to
wait, and the high cost of conducting clinical trials will be
minimized.

is overpowered, it could lead to unnecessary exposure of
many patients to a potentially harmful compound when
the drug, in fact, is not effective. Adaptive sample size reestimation avoids these pitfalls and can reduce the expected sample size, and in turn the cost of the study, under a
range of treatment effects. Protocols and procedures for
re-specification of sample size are well described in the
literature[4,17-21]. This type of adaptive design can arguably
reduce time and cost, but does not specifically deal with
optimizing inclusion/exclusion criteria.
Other forms of adaptation deal with allocation of
patients to particular treatment groups. A drop-the-loser
design is an adaptive design consisting of multiple stages.
At each stage, interim analyses are performed and the losers (i.e., inferior treatment groups) are dropped. Note that
this approach does not deal with patient selection but
with treatment selection. Alternatively, a play-the-winner
design increases allocation to successful treatments, based
upon preliminary results. This form of adaptive design is
most useful in multiple-arm or dose-ranging trials. They
allow a shared control group, dropping of ineffective
treatments before the end of the trial and stopping the
trial early if sufficient evidence of a treatment being superior to control is found[22]. These now classical kinds of
adaptive designs refine how many randomly selected patients are placed in known treatment groups. They do not
refine patient selection criteria based upon biomarkers or
traits that contain information about how individual patients are likely to respond to individual treatment.
Biomarker adaptive designs, currently being developed, allow adaptations according to biomarkers that
indicate biologic or pharmacologic response to a therapeutic intervention. In one application biomarkers may
serve as surrogate end points that predict outcomes such
as long-term survival[23]. In another application, envisioned in the present study, biomarkers can be used to
select the most appropriate target population. Recently,
Jiang et al[24] proposed a statistically rigorous biomarkeradaptive threshold phase Ⅲ design, in which a putative
biomarker is used to identify patients who are sensitive to
the new agent. The biomarker is measured on a continuous or graded scale, and a cut point established to define
the sensitive subpopulation. Using a proportional hazards
model that describes the relationship among outcome,
treatment, and biomarker value for a two-treatment clinical trial, they found that when the proportion of sensitive patients as identified by the biomarker is low, the
proposed design provided a substantial improvement in
efficiency compared with the traditional trial design. Drs.
Freidlin et al[9] proposed a new adaptive design for randomized clinical trials of targeted agents in settings where
an assay or signature that identifies sensitive patients is
not available at the outset of the study. They concluded
that when the proportion of patients sensitive to the new
drug is low, the adaptive design substantially reduces the
chance of false rejection of effective new treatments.
This prior work, as well as the present study, supports the
idea that biomarkers can add substantial value to current
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Coefficients for an approximately optimal linear
classifier
k
Let the linear classifier x =i = 1a x for dichotomous predictive
variables xi (0,1) and for xi independent or poorly correlated, based upon pilot data. Treat the coefficients, ai, as
variables to be optimized for best discrimination of nonresponders, NR, from responders, R. The mean values
k
fromk pilot data for these subgroups are xNR = aixiNR and
i=1
xR = aixiR , and the difference in means between respondi=1
ers and non-responders for the classifier is
i i

Δ x = xR - xNR =

k

ai (xR - xiNR).

i=1

For dichotomous variables the mean value XiR is the
equal to the proportion, piR, of responders for whom xi
= 1, and mean value XiNR is the equal to the proportion,
piNR, of non-responders for whom xi = 1. Then
Δx=

k

ai (pR - piNR) =

i=1

k
i=1

aibi,

for constants, bi, derived from pilot data.
Let V(X) = the variance of random variable, X, and
2
2
let us choose the ai so that S = (Δx) /V (Δx) is maximized as a measure of the separation of classes NR and
R in the x-domain. Here the variance estimate from the
given pilot data representing nNR non-responders and nR
responders to experimental therapy (with independent xi)
is
k

k

piNR (1 - piNR)
piR (1 - piR) = ai2ci ,
+
i=1
i=1
nNR
nR
for constants, ci, derived from pilot data. Hence, using
the estimate for the variance in the denominator,

V (Δx) =

ai2

2

k

bici

i=1

2

S

k
i=1

.

2

ai ci

To maximize (or minimize) S2 in the a1, a2, …. ak domain,
we can solve the set of normal equations dS2/da1 = 0,
2
2
dS /da2 = 0,... dS /da1 = 0 obtained by setting the partial
derivatives equal to zero, where for any particular dichotomous variable, i,
2

dS
= 0
dai

120

2bi
k

k

ai2ci
i=1

2aici

aibi

i=1

-

k

k

2

a ib i

i=1

2

ai2ci
i=1
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more with less. This example shows, using a model-based approach, how to
minimize the time and cost of a clinical trial by selection of optimal patient inclusion criteria. Clear cost minimums exist for realistic scenarios with potential
cost savings in millions of dollars. As the response rate for controls approaches
50%, the proper choice of inclusion criteria can mean the difference between a
successful trial and a failed trial, no matter what the cost.

or

bi -

aici .

k

aibi

i=1
k

≈ 0 for i = 1, 2, … k,

Terminology

2

ai ci

Adaptive trial design: a clinical trial design that allows modification of aspects of
the trial as it continues, based upon accumulating data in a statistically and intellectually valid way. Type II statistical error: failure to reject the null hypothesis
when it is false, that is, a false negative interpretation of a research study.

i=1

which gives a set of k equations with k unknown variables, ai, and 2k known variables, bi and ci, derived from
the pilot data.
Two solutions are evident from simple inspection
of the forgoing normal equations. Trivially, if bi = 0 for
all i, that is if piR = piNR, then we have a minimum with
S2 = (Δx)2/V (Δx) = 0 . However, if ai = bi = piR - piNR ,
and if ci ≈ c, a constant (as is reasonable from inspection
of the expression for the variance of proportions not too
close to zero or one), we have an approximate solution to
the normal equations for a maximum S2, given the bi ≠
0 and ci ≠ 0 from the training data. Thus we can expect
roughly maximal separation of populations NR and R in
the x domain if

Peer review

The topic is novel and one that is much welcomed in this space. The thinking is
in the right direction.
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